Payment overview · 2025
General Payments
$245.00
6 reported records · 3 companies
Healthcare provider profile · identity verified
Brian Paul Krier, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RAYVILLE, LA · NPI 1619903739
Verified facts
What the public records show
CMS Open Payments records show Brian Paul Krier, M.D. received $245.00 in general payments during 2025 across 6 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 82.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $202.39 | 82.6% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.03 | 9.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.58 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.00 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $202.39 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 189 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
189 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 536 | 63 |
| Potassium Chloride | Potassium Chloride | 488 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 76 |
| Gabapentin | Gabapentin | 465 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 452 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 63 |
| Famotidine | Famotidine | 309 | 57 |
| Donepezil Hcl | Donepezil Hcl | 262 | 41 |
| Losartan Potassium | Losartan Potassium | 249 | 39 |
| Lisinopril | Lisinopril | 247 | 39 |
| Furosemide | Furosemide | 226 | 54 |
| Memantine Hcl | Memantine Hcl | 216 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 30 |
| Sertraline Hcl | Sertraline Hcl | 208 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 31 |
| Trazodone Hcl | Trazodone Hcl | 199 | 32 |
| Tramadol Hcl | Tramadol Hcl | 192 | 45 |
| Rexulti | Brexpiprazole | 189 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 29 |
| Carvedilol | Carvedilol | 149 | 26 |
| Metformin Hcl | Metformin Hcl | 144 | 25 |
| Omeprazole | Omeprazole | 141 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 23 |
| Jardiance | Empagliflozin | 118 | suppressed |
| Prednisone | Prednisone | 109 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 21 |
| Clonazepam | Clonazepam | 100 | 19 |
| Buspirone Hcl | Buspirone Hcl | 99 | 16 |
| Finasteride | Finasteride | 95 | 17 |
| Mirtazapine | Mirtazapine | 95 | 18 |
| Montelukast Sodium | Montelukast Sodium | 91 | 13 |
| Levetiracetam | Levetiracetam | 90 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 36 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 86 | 12 |
| Entresto | Sacubitril/Valsartan | 85 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 14 |
| Warfarin Sodium | Warfarin Sodium | 83 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 82 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 19 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 81 | suppressed |
| Olanzapine | Olanzapine | 81 | suppressed |
| Spironolactone | Spironolactone | 79 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 35 |
| Myrbetriq | Mirabegron | 74 | suppressed |
| Azithromycin | Azithromycin | 73 | 61 |
| Meloxicam | Meloxicam | 72 | suppressed |
| Pregabalin | Pregabalin | 69 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 69 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 22 |
| Allopurinol | Allopurinol | 65 | suppressed |
| Bumetanide | Bumetanide | 65 | 18 |
| Rivastigmine | Rivastigmine | 64 | 16 |
| Valsartan | Valsartan | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 62 | suppressed |
| Risperidone | Risperidone | 62 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 36 |
| Divalproex Sodium Er | Divalproex Sodium | 55 | suppressed |
| Latanoprost | Latanoprost | 55 | 16 |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 25 |
| Sucralfate | Sucralfate | 53 | suppressed |
| Levofloxacin | Levofloxacin | 52 | 37 |
| Nuplazid | Pimavanserin Tartrate | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 26 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 41 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Nystop | Nystatin | 41 | 26 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 38 | 20 |
| Carbamazepine Er | Carbamazepine | 38 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Kerendia | Finerenone | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 32 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | 20 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | 11 |
| Ramipril | Ramipril | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 15 |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 24 | 19 |
| Restasis | Cyclosporine | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Erythromycin | Erythromycin Base | 23 | suppressed |
| Fycompa | Perampanel | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Lacosamide | Lacosamide | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 17 |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Theo-24 | Theophylline Anhydrous | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.00 · 6 records | Otsuka America Pharmaceutical, Inc. | AUSTEDO XR, EPKINLY, IMBRUVICA, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error